Steele Barry G
Known title: Executive VP and CFOCIK: 0001305741
Steele Barry G's purchase track record
How the stock did after each of Steele Barry G's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 5 since March 17, 2023
Stock higher 6 months later
100%
3 months: 60%
Median 6-month return
+45.6%
3 months: +43.9%
Beat the S&P 500
100%
median +33.3% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/8/2026 | INFU | $61K | +48.5% | pending | — |
| 3/2/2026 | INFU | $19K | -3.7% | +30.4% | +11.7% |
| 5/14/2025 | INFU | $17K | +62.6% | +82.0% | +16.3% |
| 5/20/2024 | INFU | $19K | -1.8% | +38.5% | +11.0% |
| 3/17/2023 | INFU | $21K | +43.9% | +52.8% | +13.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| INFU | ▲ Buy | Option Exercise | 8,715 | $0 | 5/18/2026 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 3,800 | $34K | 5/18/2026 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 9,297 | $82K | 5/17/2026 | View on chart |
| INFU | ▲ Buy | Grant | 21,323 | $0 | 5/17/2026 | View on chart |
| INFU | ▲ Buy | Option Exercise | 7,511 | $0 | 5/16/2026 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 3,275 | $29K | 5/16/2026 | View on chart |
| INFU | ▲ Buy | Open Market | 7,000 | $61K | 5/8/2026 | View on chart |
| INFU | ▲ Buy | Open Market | 2,064 | $19K | 3/2/2026 | View on chart |
| INFU | ▲ Buy | Option Exercise | 13,636 | $0 | 5/17/2025 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 5,946 | $37K | 5/17/2025 | View on chart |
| INFU | ▲ Buy | Open Market | 3,000 | $17K | 5/14/2025 | View on chart |
| INFU | ▲ Buy | Open Market | 3,000 | $19K | 5/20/2024 | View on chart |
| INFU | ▲ Buy | Option Exercise | 7,051 | $0 | 5/18/2024 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 3,286 | $21K | 5/18/2024 | View on chart |
| INFU | ▲ Buy | Grant | 3,886 | $0 | 5/17/2024 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 1,811 | $12K | 5/17/2024 | View on chart |
| INFU | ▲ Buy | Option Exercise | 30,000 | $0 | 3/18/2023 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 13,352 | $92K | 3/18/2023 | View on chart |
| INFU | ▲ Buy | Open Market | 3,000 | $21K | 3/17/2023 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 3,270 | $28K | 5/20/2022 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 1,537 | $13K | 5/20/2022 | View on chart |
| INFU | ▲ Buy | Grant | 7,500 | $0 | 5/20/2022 | View on chart |
| INFU | ▲ Buy | Grant | 3,525 | $0 | 5/20/2022 | View on chart |
| INFU | ▲ Buy | Option Exercise | 2,821 | $0 | 5/18/2022 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 1,230 | $10K | 5/18/2022 | View on chart |
| INFU | ▼ Sell | Tax Withholding | 4,297 | $36K | 5/18/2022 | View on chart |
| INFU | ▲ Buy | Grant | 9,744 | $0 | 5/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
INFU Shares Business Overview, Emphasizes Patient-First Strategy
INFU held a discussion outlining its business model and growth plans, highlighting a patient‑first approach to its services. The company emphasized expanding its product portfolio and improving customer engagement. The talk comes as the stock is near a key support level and shows moderate momentum. Analysts see upside potential, with a target range of $15‑$18.
INFU Shares Business Overview, Emphasizes Patient-First Strategy. INFU held a discussion outlining its business model and growth plans, highlighting a patient‑first approach to its services. The company emphasized expanding its product portfolio and improving customer engagement. The talk comes as the stock is near a key support level and shows moderate momentum. Analysts see upside potential, with a target range of $15‑$18.